المؤلفون: Fang T; Engineering Center of Innovativennovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, China.; MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, China.; Department of Comparative Medicine, Affiliated Hospital of Medicine School, Nanjing Jinling Hospital, Nanjing University, Nanjing, 210002, China., Hu S; Engineering Center of Innovativennovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, China.; MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, China., Song X; Engineering Center of Innovativennovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, China.; MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, China., Wang J; Engineering Center of Innovativennovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, China.; MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, China., Zuo R; Engineering Center of Innovativennovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, China.; MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, China., Yun S; Department of Comparative Medicine, Affiliated Hospital of Medicine School, Nanjing Jinling Hospital, Nanjing University, Nanjing, 210002, China., Jiang S; Engineering Center of Innovativennovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, China. jiangshanxiang@163.com.; MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, China. jiangshanxiang@163.com., Guo D; Engineering Center of Innovativennovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, China. gdawei0123@njau.edu.cn.; MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, China. gdawei0123@njau.edu.cn.

المصدر: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Sep; Vol. 207 (2), pp. 435-451. Date of Electronic Publication: 2024 Jul 03.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

مواضيع طبية MeSH: Erlotinib Hydrochloride*/pharmacology , Erlotinib Hydrochloride*/administration & dosage , Triple Negative Breast Neoplasms*/drug therapy , Triple Negative Breast Neoplasms*/pathology , Triple Negative Breast Neoplasms*/metabolism , Neoplastic Stem Cells*/drug effects , Neoplastic Stem Cells*/metabolism , ErbB Receptors*/metabolism , ErbB Receptors*/antagonists & inhibitors , Signal Transduction*/drug effects , Monensin*/pharmacology , Cell Proliferation*/drug effects , Xenograft Model Antitumor Assays* , Drug Synergism*, Humans ; Animals ; Female ; Mice ; Cell Line, Tumor ; Phosphatidylinositol 3-Kinases/metabolism ; Cell Movement/drug effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Mice, Nude

المؤلفون: Huang S; Cancer center, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, China., Zhang J; Department of Radiology; Translational Medicine Center and Guangdong Provincial Education, Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Wu X; Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China., Liang B; The School of Food Science and Biology, Guangdong Polytechnic of Science and Trade, Guangzhou, China., Pang N; Department of Nutrition; Guangdong Provincial Key Laboratory of Food, Nutrition and Health; School of Public Health, Sun Yat-Sen University, Guangzhou, China., Yang L; Department of Nutrition; Guangdong Provincial Key Laboratory of Food, Nutrition and Health; School of Public Health, Sun Yat-Sen University, Guangzhou, China. Electronic address: yangll7@mail.sysu.edu.cn., Zhang Z; Department of Radiology; Translational Medicine Center and Guangdong Provincial Education, Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Electronic address: zhangzhf@gzhmu.edu.cn.

المصدر: Life sciences [Life Sci] 2024 Aug 15; Vol. 351, pp. 122849. Date of Electronic Publication: 2024 Jun 17.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0375521 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0631 (Electronic) Linking ISSN: 00243205 NLM ISO Abbreviation: Life Sci Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/metabolism , Erlotinib Hydrochloride*/pharmacology , Erlotinib Hydrochloride*/therapeutic use , Axl Receptor Tyrosine Kinase* , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology , Lung Neoplasms*/metabolism , Proto-Oncogene Proteins*/genetics , Proto-Oncogene Proteins*/metabolism , Receptor Protein-Tyrosine Kinases*/genetics , Receptor Protein-Tyrosine Kinases*/metabolism , Drug Resistance, Neoplasm*/genetics, Humans ; Gene Expression Regulation, Neoplastic/drug effects ; Cell Proliferation/drug effects ; Cell Line, Tumor ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; MicroRNAs/genetics ; MicroRNAs/metabolism ; Epithelial-Mesenchymal Transition/drug effects ; Epithelial-Mesenchymal Transition/genetics ; Animals ; Mice

المؤلفون: Chaudhuri A; Department of Pharmaceutical Engineering & Technology, IIT (BHU), Varanasi 221005, India., Naveen Kumar D; Department of Pharmaceutical Engineering & Technology, IIT (BHU), Varanasi 221005, India., Kumar D; Department of Pharmaceutical Engineering & Technology, IIT (BHU), Varanasi 221005, India., Kumar Agrawal A; Department of Pharmaceutical Engineering & Technology, IIT (BHU), Varanasi 221005, India. Electronic address: ashish.phe@iitbhu.ac.in.

المصدر: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2024 Aug; Vol. 201, pp. 114386. Date of Electronic Publication: 2024 Jun 29.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 9109778 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3441 (Electronic) Linking ISSN: 09396411 NLM ISO Abbreviation: Eur J Pharm Biopharm Subsets: MEDLINE

مواضيع طبية MeSH: Triple Negative Breast Neoplasms*/drug therapy , Docetaxel*/administration & dosage , Docetaxel*/pharmacology , Docetaxel*/pharmacokinetics , Nanoparticles*/chemistry , Erlotinib Hydrochloride*/administration & dosage , Erlotinib Hydrochloride*/pharmacology , Erlotinib Hydrochloride*/pharmacokinetics , Drug Synergism* , Lipids*/chemistry , Drug Liberation* , Particle Size*, Humans ; Cell Line, Tumor ; Female ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/pharmacology ; Drug Carriers/chemistry ; Cell Survival/drug effects ; Folic Acid/chemistry ; Liposomes

المؤلفون: Aye PS; Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand., Barnes J; School of Pharmacy, University of Auckland, Auckland, New Zealand., Laking G; Te Aka Mātauranga Matepukupuku Centre for Cancer Research, University of Auckland, Auckland, New Zealand., Cameron L; Department of Medical Oncology, Te Pūriri o Te Ora Regional Cancer and Blood Service, Te Whatu Ora Health New Zealand, Auckland City Hospital, Auckland, New Zealand., Anderson M; Department of Medical Oncology, Te Whatu Ora Health New Zealand Te Pae Hauuora o Ruahine o Tararua, Palmerston North Hospital, Palmerston North, New Zealand., Luey B; Wellington Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital, Coast and Hutt Valley, Wellington Hospital, Wellington, New Zealand., Delany S; Department of Oncology, Te Whatu Ora Health New Zealand Nelson Marlborough, Nelson Hospital, Nelson, New Zealand., Harris D; Oncology Service, Te Whatu Ora - Waitaha Canterbury, Christchurch Hospital, Christchurch, New Zealand., McLaren B; Southern Blood and Cancer Service, Te Whatu Ora Southern, Dunedin Hospital, Dunedin, New Zealand., Brenman E; Cancer and Haematology Services, Te Whatu Ora Health New Zealand Haora a Toi Bay of Plenty, Tauranga Hospital, Tauranga, New Zealand., Wong J; Cancer Services, Te Whatu Ora Health New Zealand Waikato, Waikato Hospital, Hamilton, New Zealand., Lawrenson R; Medical Research Centre, University of Waikato, Hamilton, New Zealand., Arendse M; Department of Pathology, Te Whatu Ora Health New Zealand Waikato, Waikato Hospital, Hamilton, New Zealand., Tin Tin S; Department of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand., Elwood M; Department of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand., Hope P; Lung Foundation New Zealand, Manukau, Auckland, New Zealand., McKeage MJ; Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand.; Department of Medical Oncology, Te Pūriri o Te Ora Regional Cancer and Blood Service, Te Whatu Ora Health New Zealand, Auckland City Hospital, Auckland, New Zealand.; Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand.

المصدر: JMIR research protocols [JMIR Res Protoc] 2024 Jul 02; Vol. 13, pp. e51381. Date of Electronic Publication: 2024 Jul 02.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: JMIR Publications Country of Publication: Canada NLM ID: 101599504 Publication Model: Electronic Cited Medium: Internet ISSN: 1929-0748 (Electronic) Linking ISSN: 19290748 NLM ISO Abbreviation: JMIR Res Protoc Subsets: MEDLINE

مواضيع طبية MeSH: Erlotinib Hydrochloride*/therapeutic use , Erlotinib Hydrochloride*/adverse effects , Gefitinib*/therapeutic use , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/mortality , ErbB Receptors*/genetics , ErbB Receptors*/antagonists & inhibitors , Mutation*, Humans ; Retrospective Studies ; New Zealand ; Female ; Male ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/adverse effects ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/adverse effects ; Cohort Studies ; Middle Aged ; Aged

المؤلفون: Riazi Bonab H; Department of Chemistry, Faculty of Basic Sciences, Azarbaijan Shahid Madani University, Tabriz, Iran., Abbas Matin A; Department of Chemistry, Faculty of Basic Sciences, Azarbaijan Shahid Madani University, Tabriz, Iran. Electronic address: matinchem@gmail.com., Heidari H; Department of Chemistry, Faculty of Basic Sciences, Azarbaijan Shahid Madani University, Tabriz, Iran., Soylak M; Erciyes University, Faculty of Sciences, Department of Chemistry, 38039 Kayseri, Türkiye; Technology Research and Application Center (ERU-TAUM), Erciyes University, 38039 Kayseri, Türkiye; Turkish Academy of Sciences (TUBA), Çankaya, Ankara, Türkiye.

المصدر: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences [J Chromatogr B Analyt Technol Biomed Life Sci] 2024 Jul 01; Vol. 1241, pp. 124185. Date of Electronic Publication: 2024 Jun 03.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101139554 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-376X (Electronic) Linking ISSN: 15700232 NLM ISO Abbreviation: J Chromatogr B Analyt Technol Biomed Life Sci Subsets: MEDLINE

مواضيع طبية MeSH: Limit of Detection* , Rubber*/chemistry , Antineoplastic Agents*/blood , Antineoplastic Agents*/chemistry , Erlotinib Hydrochloride*/blood , Erlotinib Hydrochloride*/chemistry, Chromatography, High Pressure Liquid/methods ; Reproducibility of Results ; Humans ; Linear Models ; Dasatinib/blood ; Dasatinib/chemistry ; Hydroxides/chemistry ; Imidazoles/chemistry ; Imidazoles/blood ; Adsorption ; Solid Phase Extraction/methods ; Cobalt/chemistry ; Cobalt/blood ; Nanostructures/chemistry ; Zeolites

المؤلفون: Ramaswamy A; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Bhargava P; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Srinivas S; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Kapoor A; Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India., Mishra BK; Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India., Gupta A; Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India., Mandavkar S; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Kannan S; Department of Statistics, Advanced Centre for Treatment, Research and Education in Cancer, Homi Bhabha National Institute (HBNI), Mumbai, India., Chaugule D; CRC, Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Patil R; CRC, Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Parulekar M; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Nashikkar C; Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Ankathi SK; Department of Radiology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Kaushal RK; Department of Pathology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Naughane D; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Daddi A; Department of Medicine, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Mer N; CRC, Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Shetty N; Department of Radiology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Ostwal V; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Sep 20; Vol. 42 (27), pp. 3218-3227. Date of Electronic Publication: 2024 Aug 05.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Bevacizumab*/administration & dosage , Bevacizumab*/adverse effects , Erlotinib Hydrochloride*/administration & dosage , Erlotinib Hydrochloride*/adverse effects , Erlotinib Hydrochloride*/therapeutic use , Gallbladder Neoplasms*/drug therapy , Gallbladder Neoplasms*/pathology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Cholangiocarcinoma*/drug therapy , Gemcitabine*, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Progression-Free Survival ; Bile Duct Neoplasms/drug therapy ; Bile Duct Neoplasms/pathology

المؤلفون: Ok O; Department of Nursing, Graduate School of Clinical Nursing Science, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea., Lee M; Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.; Center for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Kim N; Department of Nursing, Graduate School of Clinical Nursing Science, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea.; Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.; Cancer Education Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Cho J; Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.; Center for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.; Cancer Education Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Hong SY; Department of Nursing, Graduate School of Clinical Nursing Science, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea., Nam MS; Department of Nursing, Graduate School of Clinical Nursing Science, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea., Yi MS; Department of Nursing, Graduate School of Clinical Nursing Science, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea., Oh D; Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Ahn JS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Kang D; Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea. dbee.kang@skku.edu.; Center for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. dbee.kang@skku.edu.; Trend Sensing & Risk Modeling Center, Institution of Quality of Life in Cancer, Samsung Medical Center, Seoul, South Korea. dbee.kang@skku.edu., Hong JH; Department of Nursing, Graduate School of Clinical Nursing Science, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea. jhee.hong@samsung.com.

المصدر: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2024 Sep 09; Vol. 32 (10), pp. 645. Date of Electronic Publication: 2024 Sep 09.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer International Country of Publication: Germany NLM ID: 9302957 Publication Model: Electronic Cited Medium: Internet ISSN: 1433-7339 (Electronic) Linking ISSN: 09414355 NLM ISO Abbreviation: Support Care Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/mortality , Carcinoma, Non-Small-Cell Lung*/pathology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/mortality , Protein Kinase Inhibitors*/administration & dosage , Protein Kinase Inhibitors*/therapeutic use , Protein Kinase Inhibitors*/adverse effects , Protein Kinase Inhibitors*/pharmacology , ErbB Receptors*/antagonists & inhibitors , Gefitinib*/administration & dosage , Gefitinib*/therapeutic use , Gefitinib*/pharmacology , Erlotinib Hydrochloride*/administration & dosage , Erlotinib Hydrochloride*/pharmacology , Erlotinib Hydrochloride*/therapeutic use, Humans ; Male ; Female ; Prospective Studies ; Middle Aged ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Afatinib/administration & dosage ; Afatinib/therapeutic use ; Afatinib/pharmacology ; Cohort Studies ; Aged, 80 and over ; Adult

المؤلفون: Barsouk A; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: abarsouk@gmail.com., Elghawy O; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Heidlauf A; Perelman School of Medicine, University of Pennsylvania Philadelphia, PA, USA., Yu C; Perelman School of Medicine, University of Pennsylvania Philadelphia, PA, USA., Wang L; Perelman School of Medicine, University of Pennsylvania Philadelphia, PA, USA., Yang D; Perelman School of Medicine, University of Pennsylvania Philadelphia, PA, USA., Kurian M; Perelman School of Medicine, University of Pennsylvania Philadelphia, PA, USA., Goel K; Perelman School of Medicine, University of Pennsylvania Philadelphia, PA, USA., Rushkin L; Perelman School of Medicine, University of Pennsylvania Philadelphia, PA, USA., Anran Huang A; Perelman School of Medicine, University of Pennsylvania Philadelphia, PA, USA., Reed-Guy L; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Bleiberg B; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Sun L; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Singh A; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Cohen RB; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Aggarwal C; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Marmarelis M; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Langer C; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.

المصدر: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2024 Sep; Vol. 195, pp. 107926. Date of Electronic Publication: 2024 Aug 10.

نوع المنشور: Journal Article; Comparative Study

بيانات الدورية: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Afatinib*/therapeutic use , ErbB Receptors*/genetics , Erlotinib Hydrochloride*/therapeutic use , Erlotinib Hydrochloride*/administration & dosage , Erlotinib Hydrochloride*/adverse effects , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology , Lung Neoplasms*/mortality , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/mortality , Carcinoma, Non-Small-Cell Lung*/pathology , Acrylamides*/therapeutic use , Mutation* , Aniline Compounds*/therapeutic use , Protein Kinase Inhibitors*/therapeutic use , Protein Kinase Inhibitors*/adverse effects, Humans ; Male ; Female ; Retrospective Studies ; Aged ; Middle Aged ; Aged, 80 and over ; Adult ; Treatment Outcome ; Indoles ; Pyrimidines

المؤلفون: Tang LWT; Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Groton, Connecticut lloydweitat.tang@pfizer.com., Shi Y; Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Groton, Connecticut., Sharma R; Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Groton, Connecticut., Obach RS; Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Groton, Connecticut.

المصدر: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Aug 14; Vol. 52 (9), pp. 1020-1028. Date of Electronic Publication: 2024 Aug 14.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE

مواضيع طبية MeSH: Aldehyde Oxidase*/metabolism , Aldehyde Oxidase*/antagonists & inhibitors , Erlotinib Hydrochloride*/pharmacology , Erlotinib Hydrochloride*/pharmacokinetics , Drug Interactions*/physiology, Humans ; Hepatocytes/metabolism ; Hepatocytes/drug effects ; Microsomes, Liver/drug effects ; Microsomes, Liver/metabolism ; Protein Kinase Inhibitors/pharmacokinetics ; Protein Kinase Inhibitors/pharmacology

المؤلفون: Kumar P; Department of Pharmaceutics, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi 110017, India; Centre for Advanced Formulation and Technology, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi 110017, India., Mangla B; Department of Pharmaceutics, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi 110017, India; Centre for Advanced Formulation and Technology, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi 110017, India. Electronic address: bhartipharmacy@gmail.com., Akthar Imam S; Centre for Advanced Formulation and Technology, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi 110017, India., Aggarwal G; Department of Pharmaceutics, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi 110017, India; Centre for Advanced Formulation and Technology, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi 110017, India. Electronic address: geetaaggarwal17@gmail.com.

المصدر: International journal of pharmaceutics [Int J Pharm] 2024 Oct 25; Vol. 664, pp. 124588. Date of Electronic Publication: 2024 Aug 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 7804127 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3476 (Electronic) Linking ISSN: 03785173 NLM ISO Abbreviation: Int J Pharm Subsets: MEDLINE

مواضيع طبية MeSH: Erlotinib Hydrochloride*/administration & dosage , Erlotinib Hydrochloride*/pharmacokinetics , Fluorescent Dyes*/administration & dosage , Fluorescent Dyes*/chemistry , Fluorescent Dyes*/pharmacokinetics , Drug Carriers*/chemistry , Optical Imaging*/methods , Nanoparticles*/chemistry, Animals ; Tissue Distribution ; Administration, Oral ; Mice ; Lipids/chemistry ; Indoles/pharmacokinetics ; Indoles/administration & dosage ; Indoles/chemistry ; Oleic Acid/chemistry ; Male